Prega

Neuropathic pain including diabetic peripheral neuropathy & post-herpetic neuralgia in adults. Adjunctive therapy of partial seizures w/ or w/o secondary generalisation in adults. Generalised anxiety disorder (GAD) in adults. Fibromyalgia management.

150-600 mg/day in 2-3 divided doses. Neuropathic pain Initially 150 mg/day, may increase to 300 mg/day after 3-7 days interval & if needed, to max dose of 600 mg/day after an additional 7-day interval. Epilepsy Initially 150 mg/day, may increase to 300 mg/day after 1 wk. Max dose of 600 mg/day may be achieved after an additional wk. GAD Initially 150 mg/day, may increase to 300 mg/day after 1 wk then 450 mg/day following an additional wk. Max dose of 600 mg/day may be achieved after an additional wk. Fibromyalgia Recommended dose: 300-450 mg/day. Initially 75 mg bd, may increase to 150 mg bd w/in 1 wk based on efficacy & tolerability. If benefit is insufficient w/ 300 mg/day, may further increase to 225 mg bd. Renal impairment CrCl ≥60 mL/min Initially 150 mg/day bd-tds. Max: 600 mg/day, ≥30-<60 mL/min Initially 75 mg/day bd-tds. Max: 300 mg/day, ≥15 to <30 mL/min Initially 25-50 mg/day once daily to bd. Max: 150 mg/day, <15 mL/min Initially 25 mg once daily. Max: 75 mg/day. Patient receiving haemodialysis In addition to daily dose, immediately give supplementary dose following every 4 hr haemodialysis treatment. Supplementary dose: 25 mg single dose. Max: 100 mg.

May be taken with or without food.

Hypersensitivity.

Immediately discontinue use if angioedema symptoms (eg, facial, perioral or upper airway swelling) occur. Not to be taken by patients w/ rare hereditary problems of galactose intolerance, the Lapp-lactase deficiency or glucose-galactose malabsorption. May need to adjust hypoglycaemic medications in diabetic patients who gain wt on pregabalin treatment. Possible dizziness & somnolence which may increase occurrence of accidental injury in elderly; loss of consciousness, confusion & mental impairment. Possible transient visual blurring & other visual acuity changes; discontinuation may result in resolution or improvement of these visual symptoms. Possible w/drawal symptoms after discontinuation of short-term & long-term treatment. Carefully evaluate patients for history of drug abuse & observe for signs of misuse or abuse (eg, tolerance development, dose escalation, drug-seeking behaviour). Possible renal function improvement following discontinuation or dose reduction. Severe CHF patients. Discontinue use if myopathy is diagnosed/suspected or markedly elevated creatine kinase levels occur in the context of myopathy symptoms. Possible suicidal ideation & behaviour; monitor & consider appropriate treatment for signs of suicidal ideation & behaviours. Risk of CNS depression when concomitantly used w/ opioids; monitor for symptoms of resp depression & sedation; consider initiating pregabalin at low dose. May influence ability to drive or use machines. Higher risk of severe AR (eg, serious resp depression) in patients w/ renal impairment. Use effective contraception in women of child-bearing potential. Pregnancy. Not recommended to breast-feed during treatment. Not recommended in childn & adolescents. Elderly patients may require dose reduction due to decreased renal function.

Dizziness, somnolence. Nasopharyngitis; increased appetite; euphoric mood, confusion, irritability, depression, disorientation, insomnia, decreased libido; ataxia, abnormal coordination, tremor, dysarthria, amnesia, memory impairment, disturbance in attention, paraesthesia, hypoesthesia, sedation, balance disorder, lethargy; blurred vision, diplopia; vertigo; vomiting, constipation, flatulence, abdominal distension, dry mouth; muscle cramp, arthralgia, back & limb pain, cervical spasm; peripheral oedema, oedema, abnormal gait, fall, drunk & abnormal feeling, fatigue; increased wt.

May potentiate effects of ethanol & lorazepam. Additive in cognitive & gross motor function impairment caused by oxycodone. Possible resp failure, coma & death when concomitantly taken w/ other CNS depressants including patients who are substance abusers. May reduce lower GI tract function (eg, intestinal obstruction, paralytic ileus, constipation) when co-administered w/ medications that have potential to produce constipation (eg, opioid analgesics).

Anticonvulsants

N02BF02 - pregabalin ; Belongs to the class of gabapentinoids. Used to relieve pain and other conditions.

POM